Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Deferred Tax (2016 - 2025)

Amphastar Pharmaceuticals has reported Long-Term Deferred Tax over the past 13 years, most recently at $42.5 million for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $42.5 million for Q4 2025, down 40.3% from a year ago — trailing twelve months through Dec 2025 was $42.5 million (down 40.3% YoY), and the annual figure for FY2025 was $42.5 million, down 40.3%.
  • Long-Term Deferred Tax for Q4 2025 was $42.5 million at Amphastar Pharmaceuticals, down from $71.1 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for AMPH hit a ceiling of $71.1 million in Q4 2024 and a floor of $22.0 million in Q3 2021.
  • Median Long-Term Deferred Tax over the past 5 years was $40.9 million (2023), compared with a mean of $43.0 million.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 82.45% in 2023 and later tumbled 40.3% in 2025.
  • Amphastar Pharmaceuticals' Long-Term Deferred Tax stood at $22.4 million in 2021, then skyrocketed by 72.0% to $38.5 million in 2022, then soared by 38.22% to $53.3 million in 2023, then surged by 33.56% to $71.1 million in 2024, then tumbled by 40.3% to $42.5 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $42.5 million (Q4 2025), $71.1 million (Q3 2025), and $71.1 million (Q2 2025) per Business Quant data.